Francois Cedric's Form 4 filing
Apellis Pharmaceuticals, Inc.APLS · filed Jul 16, 2025
- Accession no.
- 0001127602-25-019265
- Filed
- Jul 16, 2025
- Trade date
- Jul 14-15, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $2.81M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Francois CedricCIK 0001658080 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 14, 2025 | Common Stock | MOption exerciseAcquired | +65,203 | $4.31 | +$281,024.93 | 480,898 | Direct | |
| Jul 14, 2025 | Common Stock | SSaleDisposed | −137,465 | $20.19F2 | −$2,775,418.35 | 343,433 | Direct | |
| Jul 15, 2025 | Common Stock | MOption exerciseAcquired | +800 | $4.31 | +$3,448 | 344,233 | Direct | |
| Jul 15, 2025 | Common Stock | SSaleDisposed | −1,900 | $20.09F3 | −$38,171 | 342,333 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 14, 2025 | Common Stock | MOption exerciseDisposed | −65,203 | $0.00 | $0 | 110,335 | Direct | |
| Jul 15, 2025 | Common Stock | MOption exerciseDisposed | −800 | $0.00 | $0 | 109,535 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $20 - $20.58. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was affected.
Referenced by the price of 1 transaction in Table I.
- F3
This transaction was executed in multiple trades at prices ranging from $20 - $20.19. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was affected.
Referenced by the price of 1 transaction in Table I.